These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 9123706)
21. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249 [TBL] [Abstract][Full Text] [Related]
22. The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomy. Taylor JA; Koff SG; Dauser DA; McLeod DG BJU Int; 2006 Sep; 98(3):540-3. PubMed ID: 16925750 [TBL] [Abstract][Full Text] [Related]
23. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. Pisters LL; Leibovici D; Blute M; Zincke H; Sebo TJ; Slezak JM; Izawa J; Ward JF; Scott SM; Madsen L; Spiess PE; Leibovich BC J Urol; 2009 Aug; 182(2):517-25; discussion 525-7. PubMed ID: 19524984 [TBL] [Abstract][Full Text] [Related]
24. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Bianco FJ; Scardino PT; Stephenson AJ; Diblasio CJ; Fearn PA; Eastham JA Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):448-53. PubMed ID: 15890586 [TBL] [Abstract][Full Text] [Related]
25. Relapse after radical prostatectomy correlates with preoperative PSA velocity and tumor volume: results from a screening population. Berger AP; Deibl M; Strasak A; Bektic J; Pelzer A; Steiner H; Spranger R; Fritsche G; Bartsch G; Horninger W Urology; 2006 Nov; 68(5):1067-71. PubMed ID: 17095070 [TBL] [Abstract][Full Text] [Related]
26. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC; J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735 [TBL] [Abstract][Full Text] [Related]
27. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival. Doherty AP; Bower M; Smith GL; Miano R; Mannion EM; Mitchell H; Christmas TJ Br J Cancer; 2000 Dec; 83(11):1432-6. PubMed ID: 11076649 [TBL] [Abstract][Full Text] [Related]
28. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up. Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322 [TBL] [Abstract][Full Text] [Related]
29. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer? Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328 [TBL] [Abstract][Full Text] [Related]
30. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan. Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752 [TBL] [Abstract][Full Text] [Related]
31. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. Amling CL; Blute ML; Bergstralh EJ; Seay TM; Slezak J; Zincke H J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432 [TBL] [Abstract][Full Text] [Related]
32. Use of a new hypersensitive assay for the detection of prostate specific antigen in prostate cancer. Arai Y; Onishi H; Oishi K; Takeuchi H; Yoshida O Jpn J Clin Oncol; 1993 Apr; 23(2):110-5. PubMed ID: 7685834 [TBL] [Abstract][Full Text] [Related]
33. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Blute ML; Bostwick DG; Bergstralh EJ; Slezak JM; Martin SK; Amling CL; Zincke H Urology; 1997 Nov; 50(5):733-9. PubMed ID: 9372884 [TBL] [Abstract][Full Text] [Related]
34. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence. Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456 [TBL] [Abstract][Full Text] [Related]
35. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502 [TBL] [Abstract][Full Text] [Related]
36. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Partin AW J Urol; 2006 Oct; 176(4 Pt 1):1404-8. PubMed ID: 16952644 [TBL] [Abstract][Full Text] [Related]
37. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy. Gonzalez CM; Roehl KA; Antenor JV; Blunt LW; Han M; Catalona WJ Urology; 2004 Oct; 64(4):723-8. PubMed ID: 15491709 [TBL] [Abstract][Full Text] [Related]
38. Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer. Okegawa T; Nutahara K; Higashihara E J Urol; 2000 Apr; 163(4):1183-8. PubMed ID: 10737491 [TBL] [Abstract][Full Text] [Related]
39. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy. Kamat AM; Babaian K; Cheung MR; Naya Y; Huang SH; Kuban D; Babaian RJ J Urol; 2003 Nov; 170(5):1860-3. PubMed ID: 14532793 [TBL] [Abstract][Full Text] [Related]
40. Should we replace the Gleason score with the amount of high-grade prostate cancer? Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]